Gufic Biosciences Limited

NSE: GUFICBIO · Healthcare

Gufic Biosciences Limited Share Price & Analysis

369.95 +4.40%Updated 5 Jun 2026, 05:02 pm IST
LTP
369.95
+4.4%
Open
High
378
Low
358
Close
₹369.95
52W High
₹409
52W Low
₹268
Volume
244K
Lot Size
1
Sector
Healthcare
Market Cap
₹3K Cr
Face Value
₹1
Small Cap

Price Chart

Fundamentals

P/E
54.4
Sector P/E
48.9
P/B
5.58
EPS
₹4.99
ROE
10.1%
ROCE
12.3%
D/E Ratio
0.61
Div Yield
0.03%
Book Value
₹66.3

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,783
₹4.3L Cr34.45.121620.50.07
DIVISLAB
Divi's Laboratories Limited
6,616
₹1.7L Cr66.110.4816.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
4,416
₹1.5L Cr66.417.8127.615.40.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,315
₹1.2L Cr59.512.6222.117.90.88
CIPLA
Cipla Limited
1,402
₹1.1L Cr27.33.2912.416.60.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,091
₹1.1L Cr204.0521.221.20.38
DRREDDY
Dr. Reddy's Laboratories Limited
1,283
₹1.1L Cr25.42.8311.813.60.16

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

GUFICBIO · as of Mar 2026

Promoters72.51%
FII0.31%0.01
DII3.39%0.40
Public23.79%0.41
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters72.51%72.51%72.51%72.51%72.51%72.51%
FII0.47%0.12%0.23%0.23%0.30%0.31%
DII1.72%2.20%2.38%2.51%2.99%3.39%
Public25.29%25.17%24.89%24.75%24.20%23.79%

Corporate Events

To consider and approve, inter alia, the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and financial year ended March 31, 2026, dividend and other business matters

Dividend28 May 2026

Dividend - Re 0.10 Per Share

Dividend21 Sept 2025

Annual General Meetingdividend - Re 0.10 Per Share

Dividend16 Sept 2024

Annual General Meeting/Dividend - Re 0.10 Per Share

Dividend20 Sept 2023

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹231 Cr
▼2.5%
₹237 Cr
▲5.8%
₹224 Cr
▲9.3%
₹205 Cr
▼1.4%
₹208 Cr
▲2.0%
₹204 Cr
▲0.5%
₹203 Cr
▲4.1%
₹195 Cr
Op. Profit
₹33 Cr
▼13.2%
₹38 Cr
▲15.2%
₹33 Cr
▲26.9%
₹26 Cr
▼23.5%
₹34 Cr
▼12.8%
₹39 Cr
▲8.3%
₹36 Cr
▲5.9%
₹34 Cr
OPM
14.0%
▼12.5%
16.0%
▲6.7%
15.0%
▲15.4%
13.0%
▼18.8%
16.0%
▼15.8%
19.0%
▲5.6%
18.0%
▲0.0%
18.0%
Net Profit
₹12 Cr
▼29.4%
₹17 Cr
▲30.8%
₹13 Cr
▲62.5%
₹8 Cr
▼57.9%
₹19 Cr
▼13.6%
₹22 Cr
▲4.8%
₹21 Cr
▲5.0%
₹20 Cr
EPS (₹)
1.24
▼26.2%
1.68
▲29.2%
1.3
▲68.8%
0.77
▼60.1%
1.93
▼11.1%
2.17
▲4.3%
2.08
▲4.0%
2

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024
Revenue
₹944 Cr
▲15.1%
₹820 Cr
▲1.6%
₹807 Cr
Expenses
₹793 Cr
▲15.9%
₹684 Cr
▲4.1%
₹657 Cr
Op. Profit
₹151 Cr
▲11.0%
₹136 Cr
▼9.3%
₹150 Cr
OPM
16.0%
▼5.9%
17.0%
▼10.5%
19.0%
Other Income
₹3 Cr
▼25.0%
₹4 Cr
₹0 Cr
Interest
₹37 Cr
▲48.0%
₹25 Cr
▲47.1%
₹17 Cr
Depreciation
₹31 Cr
▲47.6%
₹21 Cr
▲23.5%
₹17 Cr
PBT
₹87 Cr
▼7.4%
₹94 Cr
▼19.0%
₹116 Cr
Tax %
26.0%
▲0.0%
26.0%
▲0.0%
26.0%
Net Profit
₹64 Cr
▼8.6%
₹70 Cr
▼18.6%
₹86 Cr
EPS (₹)
6.4
▼7.9%
6.95
▼19.1%
8.59
Div Payout
0.0%
▼100.0%
1.0%
▲0.0%
1.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Sep 2025Mar 2025Mar 2024
Liabilities
Equity Capital
₹10 Cr
▲0.0%
₹10 Cr
▲0.0%
₹10 Cr
▲0.0%
₹10 Cr
Reserves
₹655 Cr
▲5.5%
₹621 Cr
▲5.1%
₹591 Cr
▲13.0%
₹523 Cr
Borrowings
₹405 Cr
▲9.8%
₹369 Cr
▲9.8%
₹336 Cr
▲0.9%
₹333 Cr
Other Liabilities
₹273 Cr
▲0.7%
₹271 Cr
▲16.8%
₹232 Cr
▲2.2%
₹227 Cr
Total Liabilities
₹1.3K Cr
▲5.6%
₹1.3K Cr
▲8.7%
₹1.2K Cr
▲7.0%
₹1.1K Cr
Assets
Fixed Assets
₹491 Cr
▼0.8%
₹495 Cr
▼2.2%
₹506 Cr
▲218.2%
₹159 Cr
CWIP
₹22 Cr
▼8.3%
₹24 Cr
▲9.1%
₹22 Cr
▼92.8%
₹307 Cr
Investments
₹2 Cr
▲0.0%
₹2 Cr
▲0.0%
₹2 Cr
▲0.0%
₹2 Cr
Other Assets
₹827 Cr
▲10.3%
₹750 Cr
▲17.2%
₹640 Cr
▲2.4%
₹625 Cr
Total Assets
₹1.3K Cr
▲5.6%
₹1.3K Cr
▲8.7%
₹1.2K Cr
▲7.0%
₹1.1K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024
Operating CF
₹123 Cr
▲1857.1%
₹-7 Cr
Investing CF
₹-71 Cr
▲30.4%
₹-102 Cr
Financing CF
₹-37 Cr
▼145.1%
₹82 Cr
Net Cash Flow
₹15 Cr
▲155.6%
₹-27 Cr
Free Cash Flow
₹52 Cr
▲144.8%
₹-116 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024
Debtor Days
115d
▼17.9%
140d
▼6.0%
149d
Inventory Days
281d
▲33.2%
211d
▲12.2%
188d
Days Payable
172d
▲11.0%
155d
▼0.6%
156d
Cash Conv. Cycle
224d
▲13.7%
197d
▲8.8%
181d
Working Capital Days
80d
▼14.0%
93d
▼4.1%
97d
ROCE
12.0%
▼7.7%
13.0%

Source: Screener.in · Lower days = better efficiency

About Gufic Biosciences Limited

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Healthcare · Pharmaceuticals & Biotechnology

Frequently Asked Questions

What is Gufic Biosciences Limited share price today?
Gufic Biosciences Limited (GUFICBIO) is currently trading at ₹369.95 on NSE, up 4.40% as of the last market session. Prices update daily after market close on MarketNetra.
Is Gufic Biosciences Limited available in F&O (Futures & Options)?
Yes, Gufic Biosciences Limited (GUFICBIO) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Gufic Biosciences Limited 52-week high and low?
Gufic Biosciences Limited's 52-week high is ₹409 and the 52-week low is ₹268. The current price of ₹369.95 is 9.5% below the 52W high.
What is Gufic Biosciences Limited P/E ratio?
Gufic Biosciences Limited's current P/E ratio is 54.4. This indicates the market is paying ₹54.4 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Gufic Biosciences Limited options?
Gufic Biosciences Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade GUFICBIO options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.